Evidence map›Paper›PMID 39178370›Full record

Trial reportJCO precision oncology2024

Kinetic Profiling of

Florence T H Wu, James T Topham, Chris J O'Callaghan, Harriet Feilotter, Hagen F Kennecke, Leylah Drusbosky, Daniel J Renouf, Derek J Jonker, Dongsheng Tu, Eric X Chen and 1 more

Abstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in JCO precision oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Florence T H WuBC Cancer, University of British Columbia, Vancouver, BC, Canada.ORCID 0000-0002-6439-4606
James T TophamBC Cancer, University of British Columbia, Vancouver, BC, Canada.
Chris J O'CallaghanCanadian Cancer Trials Group, Kingston, ON, Canada.
Harriet FeilotterCanadian Cancer Trials Group, Kingston, ON, Canada.ORCID 0000-0002-1388-2183
Hagen F KenneckeOregon Health & Science University, Portland, OR.ORCID 0000-0002-3211-0656
Leylah DrusboskyGuardant Health, Redwood City, CA.
Daniel J RenoufBC Cancer, University of British Columbia, Vancouver, BC, Canada.
Derek J JonkerThe Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada.
Dongsheng TuCanadian Cancer Trials Group, Kingston, ON, Canada.ORCID 0000-0003-4842-2184
Eric X ChenPrincess Margaret Cancer Centre, Toronto, ON, Canada.ORCID 0000-0002-4581-8848
Jonathan M LoreeBC Cancer, University of British Columbia, Vancouver, BC, Canada.ORCID 0000-0001-8189-2132

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeIn metastatic colorectal cancer (mCRC),

methodsCO.26 was a phase II clinical trial that assessed durvalumab + tremelimumab in heavily pretreated mCRC.

resultsAmong the 95 patients with

conclusionWe identified a 3.2%-6.3% prevalence of the neo-

Indexed as

Circulating Tumor DNAColorectal NeoplasmsMutationAdultAgedCanadaFemaleHumansMaleMiddle AgedNeoplasm MetastasisProto-Oncogene Proteins p21(ras)Circulating Tumor DNAProto-Oncogene Proteins p21(ras)

Identifiers

PMID39178370
PMCPMC11371075

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.